Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

M.D. Anderson Cancer Center

Status

Enrolling

Conditions

Lymphoma

Treatments

Other: Molecular Functional Portrait

Study type

Interventional

Funder types

Other

Identifiers

NCT05464823

NCI-2022-05783 (Other Identifier)

2022-0396

Details and patient eligibility

About

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Full description

Primary Objective:

• To determine the feasibility and turnaround of clinical WES and transcriptome sequencing

Secondary Objectives:

To determine the frequency of actionable DNA and RNA alterations
To determine the concordance of DNA and RNA alterations
To determine the frequency of molecularly matched therapy
To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
To determine the feasibility of molecularly matched therapy to acquired resistance alterations

Exploratory Objectives:

To determine the feasibility of prioritizing targets with precision analytics
To determine clinical outcomes in patients receiving molecularly matched therapy
To determine the role of additional emerging diagnostic technologies

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Patient Eligibility:

Inclusion Criteria:

Male/female patients who are at least 18 years of age on the day of informed consent signing.
Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
Provision of written informed consent for the study.

Exclusion Criteria: